← Back to Clinical Trials
Recruiting NCT06638645

Prolonged Hospital Stay After Thoracoscopic Anatomical Lung Resections

◆ AI Clinical Summary
Plain-language summary for patients

Trial Parameters

Condition Minimally Invasive Surgical Procedures
Sponsor University Hospital, Ghent
Study Type OBSERVATIONAL
Phase N/A
Enrollment 140
Sex ALL
Min Age 18 Years
Max Age N/A
Start Date 2024-11-12
Completion 2025-12-31
Interventions
VATS/RATS anatomical lung resection

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

In this study, the reasons for prolonged hospital stay after thoracoscopic (video- or robot-assisted) anatomical lung resections are investigated. Currently, whenever possible, these anatomical lung resections are performed thoracoscopically, as they offer significant improvements in terms of postoperative pain, number of postoperative complications, rehabilitation, tolerance for adjuvant chemotherapy, and length of hospital stay. The development of an 'Enhanced Recovery After Surgery' (ERAS) protocol for lung surgery has further reduced hospital stay and the need for opioids for analgesia. Despite the optimal implementation of the ERAS protocol, there are still patients who need to stay in the hospital longer than the median. The aim of this research is to investigate the reasons for this.

Eligibility Criteria

Inclusion Criteria: * Patients referred for elective minimally invasive (uniportal or multiportal video- or robot-assisted) anatomical lung resection (lobectomy or segmentectomy) * Informed consent obtained pre-operatively * Age 18 years or older Exclusion Criteria: * Patients younger than 18 years old * Traumatic event as indication for lung resection * Non-anatomical lung resections * Thoracotomy * Patients already hospitalized for other pathologies, pre-existent and not related to the lung surgery * Urgent/emergency procedures

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology
}